Clinical trials due to COVID-19 read out March 2020 worldwide, by stage

Published by
Matej Mikulic,
Mar 26, 2020
As of March 24, 2020, there were 315 pivotal trials of unapproved, novel drugs that are approaching readout during 2020. These studies are at risk of being compromised due to the coronavirus (Covid-19) pandemic, costing pharmaceutical companies both time and money. There were 147 active trials at risk, with an estimated cost of nearly 12 billion U.S. dollars.

Pivotal studies of novel drugs at risk due to COVID-19 pandemic as of March 24, 2020*

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

March 2020

Region

Worldwide

Survey time period

as of March 24, 2020

Supplementary notes

* Vantage searched specifically for pivotal-stage projects that have yet to receive US approval, in trials that have a 2020 primary completion date, according to clinicaltrials.gov.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interest

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Coronavirus: the pharma and medtech response "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Coronavirus: the pharma and medtech response

Pharma - before the pandemic

6

Treatments and vaccines

8

Focus: BioNTech and Moderna

7

Opinions on COVID-19 vaccines

6

Business impact

4

Medtech - before the pandemic

5

Ventilators and testing

7

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Coronavirus (COVID-19) vaccines and treatmentsCoronavirus disease (COVID-19) pandemicCoronavirus (COVID-19) in ItalyCoronavirus: impact on the global economyCoronavirus (COVID-19): impact on tech sector
All features, all contents, at all times: Learn more about our professional solutions.

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interest

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.
Menu